A Trial to Demonstrate Bioequivalence Between Semaglutide Formulation D With the DV3396 Pen-injector and Formulation B With the PDS290 Pen-injector in Subjects With Overweight or Obesity
Latest Information Update: 12 Oct 2020
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
Most Recent Events
- 08 Oct 2020 Status changed from active, no longer recruiting to completed.
- 01 May 2020 Planned End Date changed from 20 Oct 2020 to 29 Sep 2020.
- 01 May 2020 Planned primary completion date changed from 20 Oct 2020 to 29 Sep 2020.